葛兰素史克Depemokimab注射液启动III期临床 适应症为2型炎症型哮喘
药物临床试验登记与信息公示平台数据显示,GlaxoSmithKline Research & Development Limited/ 葛兰素史克(中国)投资有限公司/ Glaxo Operations UK Limited trading as Glaxo
葛兰素史克 哮喘 depemokimab depemokim 2025-10-24 18:31 3
药物临床试验登记与信息公示平台数据显示,GlaxoSmithKline Research & Development Limited/ 葛兰素史克(中国)投资有限公司/ Glaxo Operations UK Limited trading as Glaxo
葛兰素史克 哮喘 depemokimab depemokim 2025-10-24 18:31 3